Janssen Enriches Crohn's Portfolio In Deal For Protagonist's Oral IL-23 Inhibitor

 
• By Mandy Jackson

J&J's Janssen committed up to $990m plus royalties to collaborate with peptide drug developer Protagonist on an oral IL-23 inhibitor for Crohn's disease, which hits a similar target as two key assets in J&J's immunology portfolio: Stelara and the Phase III biologic guselkumab.

businessman and businesswoman are shaking hands and exchanging folder after agreement was reached

More from Deals

More from Business